Given the above limitations of this study, its findings may suggest that among patients with T2D and CKD, SGLT2 inhibitors are more effective than finerenone in reducing renal and cardiovascular endpoints, especially renal and cardiac failure events. This evidence concerns the gene SLC5A2 and chronic kidney disease.